Navigation Links
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
Date:2/14/2013

9,0834,977,450General and administrative

1,001,5381,019,7472,062,5542,129,129Total operating expenses

3,447,3083,712,8146,851,6377,106,579Loss from operations

(3,440,753)(3,701,322)(6,841,276)(7,067,870)OTHER INCOME (EXPENSE):Investment income

13,0167,23427,38722,274Interest expense

(1,360)(1,847)(3,642)(4,820)Increase in fair value of warrants

--(7,069,165)-Gain on disposition of supplies

 and equipment

-3,0004,6203,000Total other income (expense), net

11,6568,387(7,040,800)20,454Loss before income taxes

(3,429,097)(3,692,935)(13,882,076)(7,047,416)Income tax benefit

1,753,2081,068,2331,753,2081,068,233NET LOSS

$
(1,675,889)$
(2,624,702)$
(12,128,868)$
(5,979,183)Basic and diluted net loss per

 common share

$
(0.02)$
(0.08)$
(0.14)$
(0.17)Weighted average number of

 common shares outstanding used

 in computing basic and diluted

 net loss per common share

106,424,44334,900,59189,046,80634,900,591 PALATIN TECHNOLOGIES, INC.and SubsidiaryConsolidated Balance Sheets(unaudited)December 31, 2012June 30, 2012ASSETSCurrent assets:Cash and cash equivalents

$
32,850,676$
3,827,198Accounts receivable

37,99127,631Restricted cash

-350,000Prepaid expenses and other current assets

343,912532,010Total current assets

33,232,5794,736,839Property and equipment, net

285,649318,653Other assets

58,542324,992Total assets

$
33,576,770$
5,380,484LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Capital lease obligations

$
23,144$
22,277Accounts payable 

484,815294,894Accrued expenses

1,541,7292,706,496Accrued compensation

-433,333Total current liabilities

2,049,6883,457,000Capital lease obligations 

8,11619,909Deferred rent'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Continental Clinical Solutions, LLC (Continental) focuses ... at its mid-Atlantic late-phase research facility, located in ... the idea of closing patient disparities in mind. ... advances," said Continental's CEO, Saleh Stevens . ... cell line of Henrietta Lacks, dubious ethical practices ...
(Date:11/23/2014)... November 23, 2014 Apiscent Labs, ... of fine chemical ingredients to the global pharmaceutical ... of its new website, Apiscent.com. , The Apiscent.com ... Labs, clean design, easy navigation, rotating images and ... Labs stand out. , The company’s ...
(Date:11/22/2014)... 2014 RURO, Inc., a leading ... released Limfinity® version 5.1.4. , RURO’s deployment teams ... than ever in RURO’s 8 year history. Many ... enhancement. Limfinity® version 5.1.4 is the perfect example ... bug fixes! , Limfinity® 5.1.4 release highlights – ...
(Date:11/22/2014)...   , ... zu KLOX    Mariano ... Officer bestellt    KLOX ist bestens ... zugelassenen Behandlungssystems zur Wundheilung zu beginnen    , ... sehr erfreut, die folgenden personellen Veränderungen anzukündigen: ...
Breaking Biology Technology:At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3RURO Announces Limfinity® version 5.1.4 2KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5
... against osteoporosis-related fractures, including spine and hip, - Reclast reduced ... to placebo in study published in New England Journal of Medicine, - Unique ... ... - Osteoporotic fractures affect one in two women over 50(1) and are ...
... a biotechnology company developing pharmaceutical products for use ... financing deal. The majority of the funding, $2.3 ... remainder was borrowed from the Madison Development Corporation, ... a private investment firm. The funds raised will ...
... the next strange idea you hear strange: the person ... door. , ,A panel of experienced entrepreneurs speaking ... Milwaukee last Wednesday have dealt with looks and whispers ... in the audience to accept the whispers as a ...
Cached Biology Technology:Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis 2Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis 3Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis 4Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis 5Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis 6Quintessence Secures Financing 2Quintessence Secures Financing 3Lowering the fear factor for entrepreneurs, intra-preneurs 2Lowering the fear factor for entrepreneurs, intra-preneurs 3
(Date:11/4/2014)... Nov. 5, 2014 – University of Utah engineers developed ... help jet fuel produce electricity without needing to ignite ... to power portable electronics, off-grid power and sensors. , ... in the American Chemical Society journal ACS Catalysis ... a chemical reaction between a fuel and an oxygen-rich ...
(Date:11/4/2014)...   3D scanner ... Fuel3D , a developer of 3D scanning solutions, ... $6.4 million (£4 million). This funding builds on the company,s ... and paves the way for the commercial launch of the ... round was led by Chimera Partners and will be used ...
(Date:11/3/2014)... 3, 2014  NeuroSigma ® , Inc. (NeuroSigma), ... company focused on commercialization of its non-invasive ... treatment of neurological and neuropsychiatric disorders, announced today ... issued a Notice of Allowance for Mexican Patent ... by NeuroSigma and the Regents of the University ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... Education Association (SEA) is preparing to conduct the first-ever research ... debris in the North Atlantic Ocean. The ... 20-year data set previously collected by SEA that reveals a ... in the western North Atlantic Ocean. This trip ...
... from the University of Warwick has discovered taking too much ... your cholesterol by almost 10%. Selenium is a trace ... from foods such as vegetables, meat and seafood. However, when ... selenium, such as through taking selenium supplements, it can have ...
... , This release is available in French ... more than 3 times per week show a worse performance in ... of exposure to mercury show a generalised delay in cognitive, memory ... fish and canned fish and to a lesser extent in white ...
Cached Biology News:SEA to conduct expedition dedicated to measuring plastic marine debris in the North Atlantic Ocean 2Too much selenium can increase your cholesterol 2Consumption of certain fish during pregnancy associated with poorer cognitive performance 2
... cells (BTI-TN-5B1-4) derived from Trichoplusia ni ... to be capable of expressing significantly ... compared to other insect cells. High ... doubling time as adherent cultures- Quick adaptation ...
... assay system offers the following ... for batch-processing systems, Long lasting ... microplates such as 384-well and ... storage conditions ( 2 - ...
... universal lysis buffer, PCR mix, DNA polymerase ... l volume PCR reactions. This system can ... positive rod and coccus bacteria, such as ... Aureus, Streptococcus Agalactiae, and etc. With the ...
... Staining Kit is uniquely formulated to ... minimal protein modification for optimal mass ... associated with traditional silver stains are ... the reagents used do not modify ...
Biology Products: